Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascendis Pharma
Pharma
After 2 delays, FDA approves Ascendis' Yorvipath
After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the U.S.
Kevin Dunleavy
Aug 12, 2024 11:10am
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am
Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla
Jun 28, 2023 10:42am
Ascendis' hormone drug gets manufacturing-related CRL
May 1, 2023 2:32pm
